Through the first three days of this week, shares of Intuitive Surgical (NASDAQ:ISRG) skyrocketed more than 19% after the company announced it received FDA clearance for a brand-new robotic surgical system, dubbed the da Vinci Xi.
But should investors really be this excited over a new robot? Absolutely, says the Fool's Steve Symington in the video below.
While this doesn't change the frustrating health care industry dynamics that prompted Intuitive Surgical to forego issuing 2014 revenue guidance recently, Steve insists investors should be pleased Intuitive isn't simply resting on its laurels. By continuing to innovate and improve on its already-dominant robotic surgery solution, Intuitive Surgical is effectively working to solidify its position as a market leader.
When Intuitive Surgical is finally granted greater visibility and if hospitals' CapEx purse strings begin to loosen, patient investors will be there to reap the rewards. To hear Steve's full take on what this means for both Intuitive Surgical and its shareholders, please watch the video below.